Drugs / COVID-19 convalescent plasma
COVID-19 convalescent plasma
also known as
CCP · Convalescent COVID-19 Plasma · Anti- SARS-CoV-2 convalescent plasma · anti-SARS-CoV-2 plasma · convalescent plasma · CCP1 · CCP2 · Coronavirus-90 · +2 more
Trials 21
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT04516954 | Aug 2020 → Mar 2021 | COVID-19 | Vinmec Research Institute of Stem Cell and Gene Technology | Completed | No outcome recorded |
| Phase 0 | NCT04355897 | Apr → Jul 2020 | COVID-19 | The Christ Hospital | Completed | No outcome recorded |
| Phase 13 trials · 1 met primary | ||||||
| Phase 1 | NCT04397757 | May 2020 → Feb 2021 | COVID-19 | University of Pennsylvania | Completed | Met primary |
| Phase 1 | NCT04388527 | Apr 2020 → Jan 2021 | COVID-19 | University of Pennsylvania | Completed | No outcome recorded |
| Phase 1 | NCT04554992 | Mar 2020 → Dec 2023 | COVID-19 | The Methodist Hospital Research Institute | Completed | No outcome recorded |
| Phase 27 trials · 1 met primary · 3 missed | ||||||
| Phase 2 | NCT04712344 | Jan → Sep 2021 | COVID-19 | University of Erlangen-Nürnberg Medical School | Unknown | No outcome recorded |
| Phase 2 | NCT04467151 | Oct 2020 → Oct 2021 | COVID-19 | Kashif Khan | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT04524507 | Aug 2020 → Jan 2021 | COVID-19 | University of North Carolina, Chapel Hill | Completed | Met primary |
| Phase 2 | NCT04432272 | Jul → Nov 2020 | COVID-19, severe acute respiratory syndrome | Corewell Health East | Terminated | No outcome recorded |
| Phase 2 | NCT04323800 | Jun 2020 → Apr 2021 | Coronaviridae infectious disease | Johns Hopkins University | Completed | Missed primary |
| Phase 2 | NCT04375098 | May → Aug 2020 | COVID-19 | Pontificia Universidad Catolica de Chile | Completed | Missed primary |
| Phase 2 | NCT04345991 | Apr 2020 → May 2021 | COVID-19 | Assistance Publique - Hôpitaux de Paris | Completed | Missed primary |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT04395170 | Sep → Dec 2020 | COVID-19 | Lifefactors Zona Franca, SAS | Unknown | No outcome recorded |
| Phase 2/3 | NCT04374526 | May 2020 → May 2021 | COVID-19 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Completed | No outcome recorded |
| Phase 32 trials · 1 met primary | ||||||
| Phase 3 | NCT05271929 | Apr 2022 → Jan 2024 | COVID-19 | German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen | Terminated | Met primary Stop: Enrollment |
| Phase 3 | NCT04516811 | Sep 2020 → Dec 2021 | COVID-19 | South African National Blood Service | Terminated | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04642014 | Dec 2020 → Jan 2022 | — | Wroclaw Medical University | Terminated | No outcome recorded |
| Phase not stated4 trials | ||||||
| — | NCT04372368 | — | COVID-19 | University of Colorado, Denver | No longer available | No outcome recorded |
| — | NCT04338360 | — | COVID-19 | Mayo Clinic | Approved for marketing | No outcome recorded |
| — | NCT04420988 | — | COVID-19 | Rutgers, The State University of New Jersey | No longer available | No outcome recorded |
| — | NCT04358211 | — | COVID-19 | Nakhle Saba, MD | No longer available | No outcome recorded |
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 26 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | COVID-19 convalescent plasma | “Coronavirus disease 2019 (COVID-19) convalescent plasma (CCP), a passive polyclonal antibody therapeutic agent, has had mixed clinical results.” PMID 36351430 ↗ Oct 202217“COVID-19 convalescent plasma (CCP) was an early and widely adopted putative therapy for severe COVID-19.” PMID 36135380 ↗ Sep 2022 “COVID-19 convalescent plasma (CCP) is a treatment option for COVID-19.” PMID 40937925 ↗ Sep 2025 |
| Known as | Anti- SARS-CoV-2 convalescent plasma | “This randomized, controlled, double-blinded phase 2 trial will assess the efficacy and safety of Anti- SARS-CoV-2 convalescent plasma as prophylaxis following exposure to...” NCT04323800 ↗1“anti-SARS-CoV-2 convalescent plasma (CP) in” NCT04358211 ↗ |
| Known as | anti-SARS-CoV-2 plasma | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04467151 ↗ |
| Known as | CCP | “Coronavirus disease 2019 (COVID-19) convalescent plasma (CCP), a passive polyclonal antibody therapeutic agent, has had mixed clinical results.” PMID 36351430 ↗ Oct 20222“COVID-19 convalescent plasma (CCP) is a treatment option for COVID-19.” PMID 40937925 ↗ Sep 2025 “COVID-19 convalescent plasma (CCP) plus standard of care (SOC)” NCT04516811 ↗ |
| Known as | CCP1 | “High-titer Convalescent COVID-19 Plasma (CCP1)” NCT04524507 ↗ |
| Known as | CCP2 | “Standard-titer Convalescent COVID-19 plasma (CCP2)” NCT04524507 ↗ |
| Known as | Convalescent COVID-19 Plasma | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04524507 ↗ |
| Known as | convalescent plasma | “Convalescent plasma has been widely used to treat coronavirus disease 2019 (Covid-19) under the presumption that such plasma contains potentially therapeutic antibodies to...” PMID 33523609 ↗ Jan 20211“The objective of COVIPLASM trial (a nested trial in the CORIMUNO-19 COHORT) is to study the efficacy of convalescent plasma to treat SARS-COV2 infected patients.” NCT04345991 ↗ |
| Known as | Coronavirus-90 | “The goal of this study is to evaluate the safety and effectiveness of Coronavirus-90 (COVID-19) convalescent plasma for the treatment of COVID-19.” NCT04432272 ↗ |
| Known as | Human convalescent plasma | “Human convalescent plasma is an option for treatment of COVID-19” NCT04358211 ↗ |
| Known as | SARS-CoV-2 convalescent plasma | “SARS-CoV-2 convalescent plasma (CP)” NCT04358211 ↗ |
| Action | Inhibit | “may inhibit viral entry and replication” NCT04345991 ↗ |
| Modality | Protein / enzyme biologic | “Convalescent plasma is the only antibody-based therapy currently available for patients with coronavirus disease 2019 (COVID-19).” PMID 32525844 ↗ Sep 2020 |
| Route | Other | “INTERVENTION: Transfusion of at least one unit of human COVID-19 convalescent plasma using standard transfusion guidelines at any time during hospitalization.” PMID 32817978 ↗ Aug 2020 |